山东大学教师主页窦蕾 Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China Home

Home > Scientific Research > Paper Publications

Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China

Release Time:2023-10-31 Hits:

Institution:公共卫生学院
Journal:Frontiers in Immunology
Document Code:AACF629AB0EF4A22870C33F9DE38ECDF
Volume:14
Number of Words:7
Translation or Not:No
Date of Publication:2023-05

Prev One:Psychometric properties and comparison of four health utility approaches among myopia patients in China

Next One:Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China

Home

Scientific Research

Teaching Research

Awards and Honours

Enrollment Information

Student Information

My Album

Blog

Personal Information

Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China